Table 8Efficacy outcomes of placebo and active-control trials of pramlintide in type 2 diabetes

Author, yearChange in HbA1c from baseline (%)Change in weight from baseline (kg)
Riddle, 20072416 weeks16 weeks
60/120 BID-TIDPBO60/120 BID-TIDPBO
−0.7−0.34−1.6+0.7
Riddle, 20092224 Weeks24 weeks
120 TIDRAIA120 TIDRAIA
−1.1−1.30+4.7
Ratner, 20022626 weeks52 weeks52 weeks
75 TID150 TIDPBO75 TID150 TIDPBO75 TID150 TIDPBO
−0.8−0.79−0.3−0.5−0.6−0.2−0.5−1.4+1.0
Hollander, 20032590 BID120 BIDPBO90 BID120 BIDPBO90 BID120 BIDPBO
−0.54−0.68−0.3−0.35−0.62−0.22−0.5−1.25+0.6

Abbreviations: BID, 2 times per day; PBO, placebo; RAIA, rapid acting insulin analog; TID, 3 times per day.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.